These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 8314160)

  • 21. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial.
    Taylor PR; White JM; Prescott RJ; Angus B; Galloway MJ; Jackson GH; Lessells AM; Lucraft HH; Summerfield GP; Proctor SJ;
    Leuk Lymphoma; 2006 Nov; 47(11):2321-30. PubMed ID: 17107904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new effective treatment for indolent lymphoma: a pilot study with fludarabine, idarubicin and prednisone combination (FLIDA).
    Caracciolo F; Capochiani E; Papineschi F; Petrini M
    Hematol Oncol; 1997 Feb; 15(1):27-31. PubMed ID: 9378469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma.
    Case DC; Gerber MC; Gams RA; Crawford J; Votaw ML; Higano CS; Pruitt BT; Gould J
    Leuk Lymphoma; 1993; 10 Suppl():73-9. PubMed ID: 8481674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of oral idarubicin (4-demethoxidaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma.
    Errante D; Sorio R; Zagonel V; Carbone A; Monfardini S; Tirelli U
    Am J Clin Oncol; 1991 Jun; 14(3):243-5. PubMed ID: 2031512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral idarubicin in non-Hodgkin's lymphomas.
    Lopez M; Di Lauro L; Papaldo P
    Invest New Drugs; 1986; 4(3):263-7. PubMed ID: 3469170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro evaluation of the efficacy of idarubicin in human tumour cells from patients with low-grade non-Hodgkin's lymphoma.
    Aleskog A; Jonsson E; Larsson R; Nygren P; Kristensen J; Sundström C; Höglund M
    Br J Haematol; 2002 Jun; 117(3):563-8. PubMed ID: 12028023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
    van Dalen EC; Michiels EM; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2010 May; 2010(5):CD005006. PubMed ID: 20464735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
    Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study.
    Federico M; Luminari S; Gobbi PG; Sacchi S; Di Renzo N; Lombardo M; Merli F; Baldini L; Stelitano C; Partesotti G; Polimeno G; Montanini A; Mammi C; Brugiatelli M
    Eur J Haematol; 2006 Mar; 76(3):217-29. PubMed ID: 16451396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
    Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
    Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidoxorubicin vs idarubicin containing regimens in intermediate and high grade non-Hodgkin's lymphoma: preliminary results of a multicentric randomized trial.
    Brugiatelli M; Federico M; Gobbi PG; Avanzini P; Callea V; Cavanna L; De Pasquale A; Di Prisco AU; Di Rienzo N; Silingardi V
    Haematologica; 1993; 78(5):306-12. PubMed ID: 8314160
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.